US › Healthcare

Xilio Development Inc (XLO)

US · Healthcare · Biotechnology

$9.04+0.67%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$18.7M

Revenue YoY

+131.2%

Net profit

$-6.4M

EPS

$-0.33

EPS estimate

$-0.59

Net margin

-34.1%

EPS came in at -0.33 against a street estimate of -0.59 — a beat of 44.1%.

Key statistics

Market cap

$58.8M

Forward P/E

0.0

P/B

0.84

Book value

$7.79

EPS (TTM)

$-0.32

52-week high

$12.74

52-week low

$6.47

50-day MA

$9.06

200-day MA

$8.66

Beta

-0.12

Analyst view

Analysts rate Xilio Development Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $20.00.

Shareholding

Insiders

25.98%

Institutions

50.14%

Largest institutional holders

Fund	Stake
Bain Capital Life Sciences Investors, LLC	10.09%
Frazier Life Sciences Management, L.P.	6.42%
Sio Capital Management, LLC	2.32%
Vanguard Capital Management, LLC	1.88%
Adage Capital Partners Gp LLC	1.70%
Merck & Co Inc	1.61%
Stonepine Capital Management Llc	0.98%
Morgan Stanley - Brokerage Accounts	0.87%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Xilio Development Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.